• Topics

  • Formats

Published 7 October 2026

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?